Joseph Anthony Nunes

US Patent:

6495558, Dec 17, 2002

Filed:

Mar 21, 2000

Appl. No.:

09/528976

Inventors:

David M. Armistead - Sudbury MA
Jean E. Bemis - Arlington MA
Daniel Elbaum - Newton MA
Gregory J. Habgood - Merrimac MA
Perry M. Novak - Milford MA
Joseph J. Nunes - Andover MA
Leticia M. Toledo-Sherman - Somerville MA

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C09D23936

US Classification:

514272, 544321

Abstract:

The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

US Patent:

6881737, Apr 19, 2005

Filed:

Apr 10, 2002

Appl. No.:

10/120959

Inventors:

John L. Buchanan - Brookline MA, US
Joseph L. Kim - Wayland MA, US
Perry M. Novak - Milford MA, US
Joseph J. Nunes - Andover MA, US
Vinod F. Patel - Acton MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D251/16
C07D251/18
A61K031/53
A61P035/00
A61P013/12

US Classification:

514241, 544207, 544208, 544209, 544211, 544212, 544213

Abstract:

The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer and polycystic kidney disease.

US Patent:

7074789, Jul 11, 2006

Filed:

Oct 31, 2003

Appl. No.:

10/699518

Inventors:

David M. Armistead - Sudbury MA, US
Jean E. Bemis - Arlington MA, US
John L. Buchanan - Brookline MA, US
Lucian V. DiPietro - Gloucester MA, US
Daniel Elbaum - Newton MA, US
Stephanie D. Geuns-Meyer - Medford MA, US
Gregory J. Habgood - Merrimack MA, US
Joseph L. Kim - Wayland MA, US
Teresa L. Marshall - Stow MA, US
Perry M. Novak - Milford MA, US
Joseph J. Nunes - Andover MA, US
Vinod F. Patel - Acton MA, US
Leticia M. Toledo-Sherman - Venice CA, US
Xiaotian Zhu - Watertown MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 403/12
C07D 403/14
A61K 31/4155
A61P 35/04

US Classification:

514241, 544206, 544207, 544208, 544209, 544210, 544219

Abstract:

The invention relates to inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms.

US Patent:

7282504, Oct 16, 2007

Filed:

May 9, 2005

Appl. No.:

11/125614

Inventors:

David M. Armistead - Sudbury MA, US
Jean E Bemis - Arlington MA, US
Lucian V DiPietro - Gloucester MA, US
Stephanie D. Geuns-Meyer - Medford MA, US
Gregory J. Habgood - Merrimac MA, US
Joseph L. Kim - Wayland MA, US
Joseph J. Nunes - Andover MA, US
Vinod F. Patel - Acton MA, US
Leticia M. Toledo-Sherman - Venice CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 403/04
A61K 31/404

US Classification:

514275, 544122, 544323, 544324

Abstract:

The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

US Patent:

7345178, Mar 18, 2008

Filed:

Aug 4, 2006

Appl. No.:

11/499919

Inventors:

Joseph J. Nunes - Andover MA, US
Jill Milne - Brookline MA, US
Jean Bemis - Arlington MA, US
Roger Xie - Southborough MA, US
Chi B. Vu - Arlington MA, US
Pui Yee Ng - Boston MA, US
Jeremy S. Disch - Natick MA, US

Assignee:

Sirtris Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D 513/00
A01N 43/78

US Classification:

548154, 514366

Abstract:

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

US Patent:

7435823, Oct 14, 2008

Filed:

Jan 24, 2005

Appl. No.:

11/042634

Inventors:

Michele Potashman - Cambridge MA, US
Steven Bellon - Wellesley MA, US
Shon Booker - Thousand Oaks CA, US
Yuan Cheng - Newbury Park CA, US
Joseph L. Kim - Wayland MA, US
Andrew Tasker - Simi Valley CA, US
Ning Xi - Thousand Oaks CA, US
Shimin Xu - Ventura CA, US
Jean-Christophe Harmange - Andover MA, US
George Borg - Cambridge MA, US
Matthew Weiss - Boston MA, US
Brian L. Hodous - Cambridge MA, US
Russell Graceffa - Hampton NH, US
William H. Buckner - Arlington MA, US
Craig E. Masse - Cambridge MA, US
Deborah Choquette - Medford MA, US
Matthew W. Martin - Cambridge MA, US
Julie Germain - Medford MA, US
Lucian V. DiPietro - Gloucester MA, US
Stuart C. Chaffee - Cambridge MA, US
Joseph J. Nunes - Andover MA, US
John L. Buchanan - Brookline MA, US
Gregory J. Habgood - Merrimac MA, US
David C. McGowan - Woluwe St. Pierre, BE
Douglas A. Whittington - Waltham MA, US
Daniel La - Brookline MA, US
Vinod F. Patel - Acton MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 215/38
C07D 265/34

US Classification:

546153, 546 15, 544 99, 544105

Abstract:

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

7442698, Oct 28, 2008

Filed:

Jul 13, 2004

Appl. No.:

10/891636

Inventors:

John L. Buchanan - Brookline MA, US
Daniel Elbaum - Newton MA, US
Matthew W. Martin - Cambridge MA, US
David C. McGowan - Arlington MA, US
Perry M. Novak - Milford MA, US
Joseph J. Nunes - Andover MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 239/48
C07D 403/12
A61K 31/505

US Classification:

5142358, 51425214, 514275, 544122, 544295, 544323

Abstract:

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I:.

US Patent:

7504396, Mar 17, 2009

Filed:

Jun 23, 2004

Appl. No.:

10/875896

Inventors:

Joseph J. Nunes - Andover MA, US
Xiaotian Zhu - Newton MA, US
Patricia Amouzegh - Didcot, GB
Chiara Ghiron - Isola d'Arbia -Asciano, IT
David N. Johnson - Abingdon, GB
Eoin Christopher Power - Abingdon, GB

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 239/48
C07D 403/12
A61K 31/505

US Classification:

5142358, 51425211, 51425214, 51425219, 514272, 544122, 544295, 544321

Abstract:

The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.